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Aims: Inhibition of vascular smooth muscle cell (VSMC) proliferation by intracellular cAMP prevents excessive
neointima formation and hence angioplasty restenosis and vein-graft failure. These protective effects are medi-
ated via actin-cytoskeleton remodelling and subsequent regulation of gene expression by mechanisms that are
incompletely understood.Herewe investigated the role of components of the growth-regulatoryHippopathway,
speciﬁcally the transcription factor TEAD and its co-factors YAP and TAZ in VSMC.
Methods and results: Elevation of cAMP using forskolin, dibutyryl-cAMP or the physiological agonists, Cicaprost or
adenosine, signiﬁcantly increased phosphorylation and nuclear export YAP and TAZ and inhibited TEAD-
luciferase report gene activity. Similar effects were obtained by inhibiting RhoA activity with C3-transferase, its
downstream kinase, ROCK, with Y27632, or actin-polymerisation with Latrunculin-B. Conversely, expression of
constitutively-active RhoA reversed the inhibitory effects of forskolin on TEAD-luciferase. Forskolin signiﬁcantly
inhibited the mRNA expression of the pro-mitogenic genes, CCN1, CTGF, c-MYC and TGFB2 and this was reversed
by expression of constitutively-active YAP or TAZ phospho-mutants. Inhibition of YAP and TAZ function with
RNAi or Verteporﬁn signiﬁcantly reduced VSMC proliferation. Furthermore, the anti-mitogenic effects of
forskolin were reversed by overexpression of constitutively-active YAP or TAZ.
Conclusion: Taken together, these data demonstrate that cAMP-induced actin-cytoskeleton remodelling inhibits
YAP/TAZ–TEAD dependent expression of pro-mitogenic genes in VSMC. This mechanism contributes novel in-
sight into the anti-mitogenic effects of cAMP in VSMC and suggests a new target for intervention.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Vascular smooth muscle cell (VSMC) proliferation contributes to-
wards the development of various vascular diseases characterised by
pathological intima formation, including atherosclerosis, transplant vas-
culopathy and pulmonary hypertension. Increased VSMC proliferation
also contributes towards neointima formation after balloon angioplasty
with and without stenting and vein grafting, limiting long-term success
of clinical interventions designed to treat atherosclerosis. Except in the
case of restenosis, the adverse consequences of neointima formation
have remained intractable to therapy. A complete understanding of
the mechanisms regulating VSMC proliferation is therefore essential
for the development of new treatments.
The secondmessenger 3′-5′ cyclic adenosinemonophosphate (cAMP)
is synthesized in cells by adenylyl cyclase enzymes in response to vasoac-
tive Gs protein-coupled receptor stimulation. In VSMC, elevated cAMP
levels inhibit mitogen stimulated proliferation in vitro [1] and after injury
in vivo [2]. Inhibitory effects of cAMP on VSMC migration [3,4] also help
reduce intimal lesion formation in experimental vascular injury models
[2,5]. As a consequence, altered or aberrant cAMP signalling is implicated
in the development of many vascular pathologies [6,7], including late
vein-graft failure [8–10], angioplasty restenosis [11], atherogenesis [12]
and pulmonary hypertension. For example, cAMP synthesis is impaired
in response to hypertension [13], vein grafting [10], hypoxia and ox-LDL
[14], suggesting that deregulation of cAMP signalling contributes towards
the development of vascular pathologies.
Activation of the cAMP sensitive protein kinase A (PKA) and subse-
quent phosphorylation of CREB is one well-established mechanism un-
derlying cAMP-dependent cellular responses [15]. Activation of the
PKA-CREB pathway is necessary but alone insufﬁcient for inhibition of
VSMC proliferation [16,17]. Indeed, contradictory ﬁndings suggest that
CREB might also increase proliferation in some circumstances [18].
Clearly factors other than the PKA-CREB axis are involved.
Recent evidence from our laboratory and others implicates actin-
cytoskeleton remodelling as an additional and essential component of
cAMP signalling in VSMC [16,19–21]. Elevated cAMP inhibits the activity
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of members of the Rho GTPases, which in VSMC results in remodelling
of the actin-cytoskeleton and acquisition of a ‘stellate’ like morphology
[19,21]. RhoA or Rac1 inhibition using pharmacological inhibitors,
siRNA or dominant–negative approaches mimics the effects of cAMP
on VSMC morphology, proliferation, migration and relaxation in vitro
and in vivo [19,21]. Moreover, expression of constitutively-active
RhoA or Rac1 mutants prevent cAMP-induced actin-cytoskeleton re-
modelling and reverse the anti-mitogenic effects of cAMP in VSMC
[19–21], demonstrating the functional role of Rho GTPase inhibition. Al-
though inhibition of Rho GTPases and actin-remodelling is an important
mechanism underlying cAMP-dependent biological responses in VSMC,
the downstream pathways have remained unclear.
The transcriptional co-activators Yes Associated Protein (YAP) and
Transcriptional Coactivator With PDZ-Binding Motif (TAZ) have been
implicated in growth regulation in numerous cell types. Overexpression
of YAP homolog Yorkie inDrosophila induces overgrowth of ﬂy imaginal
discs [22], whilst transgenic mice overexpressing YAP develop multiple
tumours [23,24]. Likewise, several studies have linked expression of the
YAP paralog TAZ to growth regulation of numerous cell types [25–27].
Although YAP and TAZ (collectively referred to as YAP/TAZ herein)
can interact with several transcription factors, their growth promoting
properties are primarily mediated via interaction with members of the
TEAD family of transcription factors. For example, silencing of TEAD
blocks expression of themajority of YAP inducible genes and largely at-
tenuates YAP-induced overgrowth phenotype [28]. Furthermore, the
phenotype of the TEAD1/2-null mice resembles the phenotype of YAP-
null mice [29]. Likewise, in Drosophila, the TEAD-homolog mediates
the overgrowth phenotype of the YAP-homolog. The transcriptional ac-
tivity of the YAP/TAZ–TEAD complex is regulated by theHippo pathway,
which is centred on two kinases;MST1/2 and Lats1/2 [30]. In mammals,
activation of MST1/2 kinase triggers the phosphorylation and activation
of Lats 1/2 kinase, which then directly phosphorylates YAP and TAZ.
Phosphorylated YAP and TAZ bind to 14-3-3ε proteins in the cytoplasm,
thereby hindering their nuclear import and thus blocking their function.
Importantly, in mammals the activity of MST1/2 kinase appears to be
dependent on the organisation and integrity of the actin-cytoskeleton.
For example, deletion of actin capping proteins or overexpression of
actin nucleation factors in Drosophila leads to disruption of Hippo
signalling [31]. In mammals, disruption of the actin-cytoskeleton
induced by actin-depolymerising drugs or mechanical cues (impaired
cell spreading or soft matrices) or have all been shown to induce YAP/
TAZ phosphorylation [32]. In this study, we investigated if cAMP-
induced remodelling of the actin-cytoskeleton regulates the activity of
the YAP/TAZ–TEAD pathway and if this mechanism underlies the anti-
mitogenic properties of cAMP in VSMC.
2. Material and methods
2.1. Materials
Male SpragueDawley (SD) ratswere obtained fromCharles River. Cul-
ture media and additives were obtained from Invitrogen. All chemicals
were obtained from Sigma unless otherwise stated. BAY60-6583 was
from Tocris. Antibodies to YAP, phospho-YAPS127, phospho-YAPS397,
TAZ, pan-TEAD and phospho-Retinoblastoma protein were from Cell Sig-
nalling Technologies. Anti-BrDU antibody was from Sigma.
2.2. Smooth muscle cell culture
Male Sprague Dawley rats were killed by cervical dislocation in ac-
cordance with the Directive 2010/63/EU of the European Parliament.
Approval was granted by the University of Bristol ethical review
board. Surplus segments of human aortic arch were obtained from
post-mortem hearts donated for valve transplant (Research Ethical
Committee number 0/H0107/48). Medial tissue was carefully dissected
from the thoracic aorta and cut into 1 mm2 pieces for explant culture,
essentially as described previously [33]. Stimulations were performed
in 5% foetal calf serum/DMEM unless otherwise stated. Proliferation
wasmeasured by culture in the presence of 10 μMBrDU for 6 h. Follow-
ing ﬁxation in 70% ethanol, incorporated BrDU was detected by
immune-histochemical staining as previously described [16]. Typically,
all cells (at least 200) in ﬁve to ten ﬁelds of viewweremanually counted
using ImageJ software. For nuclear and cytosolic fractionation, cells
were lysed in hypotonic lysis buffer (10 mM HEPES pH 7.4, 10 mM
KCl, 1.5 mMMgCl2, 0.05% NP-40, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/
ml leupeptin) with homogenisation. Nuclei were pelleted at 1000 g
and washed in lysis buffer. Nuclear proteins were extracted in Laemmli
sample buffer (1% SDS, 10 mM Tris pH 6.8, 10% glycerol).
2.3. Quantitative RT-PCR and Western blotting
Quantiﬁcation ofmRNAandprotein levelswas performedby qRT-PCR
and Western blotting respectively, essentially as described previously
[16]. Total RNA, extracted using Ambion Pure-Link kits and was reverse
transcribed using QuantiTect RT kit (Qiagen) and random primers. Quan-
titative PCRwas performed using Roche SYBRGreen using a BioRad Roto-
Gene Q PCR machine (20′@95 °C; 20′@62 °C; 20′@72 °C). Primers se-
quences are described in supplement table 1. Data was normalised to
total RNA levels in each reaction. Primers sequences are detailed in
Table 1. Western blots were performed using a Mini-Protean II system.
Proteins were transferred to PVDF membrane using a semi-dry Turbo
blotter system (Bio-Rad) and detected using ECL and a digital ChemiDoc
imaging system (Bio-Rad). Phos-tag gels were prepared containing
100 μM Phos-tag acrylamide and 20 μM MnCl2 according to the
manufacturer's instructions (Alpha Laboratories).
2.4. Plasmids, siRNA and adenoviral vectors
TEAD reporter 8xGTIIC-luciferase was a gift from Stefano
Piccolo (Addgene plasmid #34615) [32]. TnT-minP reporter was
generated by digesting 8xGTIIC-luciferase with Kpn1 and BglII to
remove the TEAD elements followed by blunt end re-ligation. Plas-
mid pCMV-YAPS127A (Addgene plasmid #27370) [34] and pCMV-
TAZ4SA were gifts from Kunliang Guan. A 2.177 kb fragment of the
human CCN1 promoter containing two proximal TEAD elements
(Hg19;chr1:86044316–chr1:86046493) was described previously
[35] and cloned into pGL4-luciferase (Promega). −163 to +57 bp
fragments of the CCN1 promoter containing either wild type or
mutated TEAD elements have been described previously [36].
Proximal promoter regions of the CTGF (Hg19;chr6:132272455–
132272687) and TGFB2 (Hg19;chr1:21851177–218520875) pro-
moters containing consensus TEAD binding elements and TEAD
ChiP-seq binding sites (ENCODE track Txn Fac ChIP V2) were am-
pliﬁed by PCR from human genomic DNA and cloned into the
Kpn1 and Nhe1 sites of pGL4-luciferase. Recombinant adenovirus
expressing constitutively-active YAPS127A or TAZ4SA were made as
previously described by sub-cloning cDNAs from the above pCMV
vectors to pDC515 (Microbix). Adenovirus expressing active
RhoA(G14V) has been described previously [20]. Silencer Select
siRNAs targeting rat YAP (s170200 and s170198) and rat TAZ
Table 1
Primer sequences used in qPCR reactions.
Primer description Sequence (5′-3′)
Rat CCN1 forward GGAACTGGCATCTCCACACGAGTT
Rat CCN1 reverse TTGTCCACAAGGACGCACTTCACA
Rat CTGF forward GGAAATGCTGTGAGGAGTGGGTGT
Rat CTGFreverse TGTCTTCCAGTCGGTAGGCAGCTA
Rat cMYC forward GAGGAGAAACGAGCTGAAGCGTAG
Rat cMYC reverse TTCTCGCCGTTTCCTCAGTAAGTC
Rat TGFB2 forward TCCATACAGTCCCAGGTGCTCTGT
Rat TGFB2 reverse GACCCTGAACTCTGCCTTCACCAG
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(s148961) were purchased from Life Technologies. Control siRNA
was Silencer Select negative control (#4390844).
2.5. Transfection and recombinant adenoviruses transduction
Plasmid transfection was performed by electroporation using an
Amaxa Nucleofector-1.5 machine. 1 × 106 VSMC was transfected with
3–5 μg of DNA or 100 pmol of siRNA using the standard Amaxa
Nucleofector program A033. VSMCs were infected with adenovirus at
1 × 108 plaque forming units/ml for 16 h.
2.6. Reporter gene luciferase assays
Cells were transfected by electroporation with the indicated pro-
moter reporter plasmids together with pTk-Renilla for normalisation.
Cells were stimulated with the indicated agents 24 h post-transfection
Fig. 1. Elevated cAMP induces phosphorylation of YAP and TAZ inVSMC. VSMCwere stimulatedwith 25 μM forskolin (A, C, E) or 500 μMdb-cAMP (B, D, F) for the indicated times and total
cell lysates analysed byWestern blotting for phospho-YAP (S127 and S397; A, B, E, F) and total-TAZ phosphorylation (C–F). Western blots were quantiﬁed using densitometry (A–D). All
experiments are at least n = 4. * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
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followed by lysis in Promega cell culture lysis buffer. Luciferase and
Renilla activity was quantiﬁed using the dual reporter assay kit
(Promega) according to the manufacturer's instructions using Glomax
luminometer (Promega).
2.7. Statistical analysis
Statistical analysis was performed using ANOVA with Student ×
Newman × Keuls post-test or where appropriate a paired Student's
t-test. * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
3. Results
3.1. Elevated cAMP induces phosphorylation of YAP and TAZ in VSMC
Elevation of intracellular cAMP induces actin-cytoskeleton
remodelling and inhibits proliferation in VSMC [37–39]. We there-
fore hypothesised that cAMP would induce phosphorylation of
downstream Hippo pathway components, YAP and TAZ, and that
this would mediate growth arrest. Stimulation of cultured VSMC
with the adenylate cyclase agonist, forskolin or the cAMP analogue
dibutyryl-cAMP (db-cAMP) resulted in a rapid induction of a
stellate morphology and loss of actin stress ﬁbres (Supplement
Fig. 1). Forskolin or db-cAMP stimulation also resulted in a rapid
increase in YAP phosphorylation on serine-127 and -397 (Fig. 1A,
B). Increased phosphorylation at both residues was evident after
30 min with either treatment and persisted for 6 h after forskolin
stimulation and for at least 1 h after db-cAMP stimulation.
Forskolin and db-cAMP stimulation increased phosphorylation of
TAZ, detected by reduced electrophoretic mobility on Phos-tag ac-
rylamide gels (Fig. 1C, D). Again, increased phosphorylation was
evident after 30 min and persisted for at least 6 h. Total TEAD or
β-ACTIN protein levels were not affected by forskolin stimulation.
Similar increases in YAP and TAZ phosphorylation were observed
after forskolin stimulation of human VSMC (Supplement Fig.
2) and in response to the physiological GPCR agonists Cicaprost, a
prostacyclin mimetic, or BAY60-6583, an adenosine A2B-receptor
agonist (Supplement Fig. 3).
3.2. Elevated cAMP induces nuclear export of YAP and TAZ, TAZ degradation
and inhibition of TEAD-activity
We next investigated the functional consequences of cAMP-induced
YAP/TAZ phosphorylation. We initially investigated effects of elevated
cAMP on total YAP and TAZ levels, since YAP phosphorylation on
serine-397 has previously been a linked to YAP degradation [40].
However, forskolin stimulation of VSMC did not result in any detectable
change in total YAP levels over the 240 min time course studied (Fig.
2A). In contrast, TAZ levels were signiﬁcantly reduced after 120 or
240 min stimulation. We next studied the effect of forskolin on cellular
localisation of YAP/TAZ using cellular fractionation. Efﬁcient cytoplas-
mic and nuclear fractionation was conﬁrmed by detection of cytoplas-
mic GAPDH and nuclear Lamin A/C proteins (Fig. 2B). Forskolin
stimulation dramatically reduced nuclear YAP and TAZ levels after 1
and 2 h. To test whether loss of nuclear YAP/TAZ resulted in impaired
TEAD activity, we quantiﬁed the activity of a synthetic TEAD-
dependent luciferase reporter (8xGTIIC-luciferase) in response to
cAMP-elevation. Stimulation with forskolin or db-cAMP signiﬁcantly
inhibited TEAD reporter activity after 4 and 8 h; inhibition was as
early as 2 h with db-cAMP (Fig. 3A, B). Forskolin or db-cAMP treatment
did not signiﬁcantly affect the activity of a matched control reporter
vector (TnT-minP) lacking the TEAD binding elements (Fig. 3A, B).
Importantly, forced expression of constitutively-active phospho-site
mutants of YAP (YAPS127A) or TAZ (TAZ4SA) signiﬁcantly increased
basal TEAD-activity and completely reversed the inhibitory effects of
forskolin (Fig. 3C).
3.3. Inhibition of RhoA/ROCK-mediated actin polymerisation underlies
cAMP-mediated repression of YAP/TAZ and TEAD
Elevated cAMP is known to inhibit RhoA activity and actin-
polymerisation [20,21], which is involved in cAMP-inducedmorpholog-
ical changes and actin-cytoskeleton remodelling. We therefore asked
whether RhoA, its effector ROCK and actin-cytoskeleton organisation
are responsible for the effects of cAMP on YAP/TAZ phosphorylation
and inhibition of TEAD reporter activity. Incubation with the RhoA in-
hibitor, C3 transferase, the ROCK inhibitor, Y27632 or the actin-
depolymerisation agent, latrunculin-B, signiﬁcantly increased phos-
phorylation of YAP and TAZ (Fig. 4A, B and C) and signiﬁcantly inhibited
activity of TEAD-luciferase (Fig. 4D) without affecting activity of the
control reporter (TnT-minP), consistent with impaired YAP/TAZ func-
tion. Importantly, forced expression of constitutively-active RhoA,
which prevents cAMP-induced actin remodelling, signiﬁcantly reversed
the effects of forskolin on TEAD-luciferase activity (Fig. 4E).
3.4. Intracellular cAMP inhibits the expression YAP/TAZ-dependent
pro-mitogenic genes
Since elevated cAMP is known to potently inhibit cell-cycle
progression in VSMC [1,41] we sought to identify YAP/TAZ-
dependent genes that promote cell proliferation and are repressed
Fig. 2. Elevated cAMP induces YAP/TAZ nuclear export and TAZ degradation. VSMC were
stimulated with 25 μM forskolin for the indicated times. (A) Total cell lysates were
analysed fot YAP and TAZ (n = 3). (B) Cytoplasmic and nuclear fractions were analysed
for YAP, TAZ, Lamin A/C and GAPDH. *** indicates p b 0.001.
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by elevated cAMP. We initially identiﬁed all genes containing TEAD
ChIP-seq peaks (ENCODE track Txn Fac ChIP V2) within their core
(−1000 bp to +100 bp) promoters. This list was subsequently
ﬁltered to identify genes with the gene ontology tag GO:0008284
(positive regulation of proliferation), resulting in putative YAP/
TAZ–TEAD-dependent genes that are involved in the positive regu-
lation of cell proliferation. This list contained the genes CCN1, CTGF,
c-MYC and TGFβ2. The YAP/TAZ-dependence of these genes in
VSMC was initially conﬁrmed using siRNA-mediated silencing of
YAP/TAZ. Transient transfection with siRNA targeting YAP or TAZ
signiﬁcantly repressed YAP or TAZ mRNA levels (supplement ﬁg.
4), respectively, without affecting the mRNA levels of the house-
keeping genes GAPDH (Supplement Fig. 4) or 36B4 (Supplement
Fig. 5) or the non-TEAD target gene EGR1 (Supplement Fig. 5).
YAP and TAZ double knock-down signiﬁcantly repressed mRNA
levels of CCN1, CTGF, c-MYC and TGFB2, thus conﬁrming the YAP/
TAZ-dependence of these genes in VSMC (Supplement Fig. 5). We
therefore tested the hypothesis that the expression of these genes
would be repressed by elevated cAMP in VSMC. Forskolin stimula-
tion signiﬁcantly inhibited the mRNA levels of CCN1, CTGF, and
TGFB2 after 1, 2 and 4 h stimulation (Fig. 5A–D). Expression of
c-MYC was also signiﬁcantly inhibited but only after 1 h. Levels of
36B4 mRNA were unaffected by forskolin stimulation (Fig. 5E). To
test whether this inhibition was dependent on YAP and/or TAZ in-
activation, we investigated the effect of constitutively-active mu-
tants of YAP and TAZ. Forced expression of constitutively-active
YAP (YAPS127A) or TAZ (TAZ4SA) signiﬁcantly increased basal ex-
pression of all four genes (Fig. 5F–I), consistent with YAP/TAZ–
TEAD-dependent expression of these genes. More importantly,
the forskolin-mediated repression of these mRNAs was signiﬁcant-
ly reversed by YAPS127A or TAZ4SA (Fig. 5F–I). Levels of 36B4 mRNA
were unaffected by YAPS127A or TAZ4SA expression (Fig. 5J). To in-
vestigate effects on the promoter activity of these genes, we cloned
their promoter regions encompassing the proximal TEAD-binding
elements, upstream of luciferase. Forskolin-mediated inhibition
of CCN1-LUC, CTGF-LUC and TGFB2-LUC promoter activity was
similarly reversed by forced expression of YAPS127A or TAZ4SA
(Supplement Fig. 6). Taken together, these data demonstrate that
elevated cAMP represses expression of pro-mitogenic genes in
VSMC by inhibiting the activity of YAP/TAZ. Furthermore, mutation
Fig. 3.Elevated cAMP inhibited TEAD-dependent transcription. VSMCswere transfectedwith either TEAD-luciferase plasmid (8xTEAD) or TnT-minimal promoter-luciferase plasmid (TnT-
minP) that lacks TEAD elements. Cells were stimulated with 25 μM forskolin (A and C) or 500 μM db-cAMP (B) for the indicated times. Cell lysates were assayed for luciferase activity.
(C) VSMCswere transfectedwith TEAD-luciferase plasmid together with active YAP (YAPS127A), active TAZ (TAZ4SA), or empty control vector. The cells ere stimulatedwith 25 μM forskolin
for 8 h. All data is n = 3 * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
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of TEAD-binding element 1 in the CCN1 promoter signiﬁcantly
inhibited CCN1 promoter activity (Supplement Fig. 7), consistent
with a functional role for TEAD in CCN1 expression in VSMC.
3.5. Inhibition of YAP and TAZ underlies cAMP anti-mitogenesis in VSMC
Wenext tested the functional importance of YAP/TAZ for VSMC pro-
liferation and cAMP-mediated growth arrest. VSMC were transiently
transfected with siRNA targeting YAP, TAZ or both YAP and TAZ togeth-
er. YAP siRNA and TAZ siRNA signiﬁcantly inhibited themRNA (Supple-
ment Fig. 4) and protein levels (Fig. 6A) of YAP and TAZ respectively,
whilst dual YAP/TAZ siRNA signiﬁcantly repressed bothproteins. Impor-
tantly, expression of GAPDH or ACTIN protein remained unaffected.
Silencing of YAP or TAZ resulted in a signiﬁcant reduction in the levels
of hyper-phosphorylated retinoblastomaprotein (Rb), amarker of tran-
sition through theG1-S phase checkpoint. Dual silencing of YAP/TAZ had
an additive effect, further reducing phospho-Rb levels (Fig. 6A and B).
Silencing of YAP or TAZ also resulted in a signiﬁcant inhibition of
VSMC proliferation (quantiﬁed by BrDU incorporation), whilst dual si-
lencing of YAP/TAZ again had an additive effect (Fig. 6C and Supplement
Fig. 8). Taken together, these data demonstrate that both YAP and TAZ
are important mediators of VSMC proliferation.
To further conﬁrm the functional importance of YAP/TAZ in VSMC
proliferation we treated cells with the benzoporphyrin derivative,
Verteporﬁn (VP), which has been shown to disrupt the interaction be-
tween YAP and TEAD [42]. We initially conﬁrmed this in VSMC using
YAP–TEAD pull-down assays (Supplement Fig. 9). VSMCs were
transfected with GFP-YAP followed by treatment with VP for 2 h. GFP-
YAP was afﬁnity puriﬁed using GFP-Trap beads and co-puriﬁed TEAD
quantiﬁed byWestern blotting. These assays conﬁrmed that VP inhibits
the interaction between YAP and TEAD in VSMC. VP treatment also
signiﬁcantly inhibited TEAD-luciferase activity in a dose-dependent
manner (Fig. 7A), consistent with disruption of the YAP–TEAD complex.
Importantly, VP treatment signiﬁcantly inhibited levels of hyper-
Fig. 4. Inhibition of RhoA/ROCK-mediated actin polymerisation underlies cAMP-mediated repression of YAP/TAZ and TEAD. VSMCs were treated with RhoA inhibitor (C3 Trans-
ferase; 2 μg/ml), ROCK inhibitor (Y-27,632; 10 μM) or actin-polymerisation inhibitor (Latrunculin B; 5 μg/ml) for 30 min and phosphorylation of YAP/TAZ was quantiﬁed West-
ern blotting (A–C). VSMCs were transfected with TEAD-luciferase plasmid (8xTEAD-LUC) or TnT-minimal promoter-luciferase plasmid (TnT-minP) and treated with indicated
RhoA/ROCK pathway inhibitors for 8 h (D). Cells infected with either active RhoA (RhoAG14V) or control adenovirus were stimulated with 25 μM forskolin for 8 h (E). All data is
n = 3. * indicates p b 0.05, ** indicates p b 0.01. ## indicates p b 0.01 and ### indicates p b 0.001 on log transformed data.
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phosphorylated-Rb protein (Fig. 7B and C) and incorporation of BrDU
(Fig. 7D and Supplement Fig. 10), further conﬁrming the involvement
of YAP/TAZ–TEAD in G1-S phase progression and proliferation in VSMC.
Lastly, we sought to test the functional importance of YAP and TAZ
for the anti-mitogenic effects of cAMP in VSMC using adenovirus-
mediated expression of constitutively-active YAP (YAPS127A) or TAZ
(TAZ4SA). Forskolin-treatment signiﬁcantly reduced levels of hyper-
phosphorylated-Rb in control adenovirus infected cells (Fig. 8A), consis-
tent with previous studies [43,44]. Forced expression of active-YAP sig-
niﬁcantly elevated basal levels of hyper-phosphorylated-Rb (p b 0.01).
Forskolin-stimulation of YAPS127A expressing cells resulted in a signiﬁ-
cant inhibition of hyper-phosphorylated-Rb (p b 0.05). However, this
was to levels signiﬁcantly higher than in forskolin stimulated control
virus infected cells (p b 0.01) and to levels that were not different
from unstimulated control virus infected cells. Overexpression of
TAZ4SA also signiﬁcantly elevated basal hyper-phosphorylated-Rb
levels. Importantly, forskolin stimulation of TAZ4SA expressing cells did
not signiﬁcantly alter hyper-phosphorylated-Rb levels (Fig. 8A). Like-
wise, forskolin stimulation of cells doubly infected with both YAPS127A
and TAZ4SA expressing adenoviruses did not result in a signiﬁcant inhi-
bition of hyper-phosphorylated-Rb (Supplement Fig. 11). Forskolin
stimulation of control adenovirus infected cells signiﬁcantly inhibited
BrDU incorporation (Fig. 8B and Supplement Fig. 12). Expression of
YAPS127A or TAZ4SA both signiﬁcantly increased basal levels of BrDU
incorporation (Fig. 8B) and completely prevented the forskolin-
mediated inhibition or BrDU incorporation (Fig. 8B). Taken together,
these data demonstrate a role for YAP and TAZ inactivation in cAMP-
mediated growth arrest.
4. Discussion
In this study, we investigated the role of Hippo pathway effector
proteins YAP, TAZ and TEAD in cAMP-mediated growth arrest in
VSMC. It was previously shown that YAP levels are elevated in both
mouse and rat arterial injury models, where expression correlates
with a synthetic VSMC phenotype [45]. We now show, using loss and
gain of function strategies, that both YAP and TAZ are essential for pro-
liferation in adult VSMC. We also demonstrate that cAMP-induced
actin-remodelling suppresses the activity of both YAP and TAZ and
that this mechanism underlies the anti-mitogenic effects of cAMP in
VSMC. In detail, elevation of cAMP using the forskolin, db-cAMP or the
GPCR agonists Cicaprost or BAY60-6583 all rapidly induced YAP phos-
phorylation (serine-127 and serine-397) and pan-TAZ phosphorylation.
This rapidly reduced nuclear YAP and TAZ levels, most likely via
impaired nuclear import or enhanced export. Consistent with the
Fig. 5. cAMP inhibits the expression YAP/TAZ-dependent pro-mitogenic genes. VSMCs were stimulated with 25 μM forskolin for the indicated times (A–F) and analysed by qRT-PCR for
CCN1 (A; n = 4), CTGF (B; n = 4), cMYC (C; n = 8), TGFB2 (D; n = 8), 36B4 (E; n = 4). Cells were infected with control adenovirus, YAPS127A adenovirus or TAZ4SA adenovirus and
stimulated with 25 μM forskolin (F–J). Expression of CCN1 (F; n = 4), CTGF (G; n = 4), cMYC (H; n = 4), TGFB2 (I; n = 4), 36B4 (J; n = 4) was analysed by qRT-PCR. * indicates
p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
Fig. 6.YAP and TAZ cooperate to regulate VSMC proliferation. VSMCwere transfectedwith
siRNA targeting YAP, TAZ or YAP plus TAZ. Total cell lysateswere prepared 24 h post trans-
fection and analysed by Western blotting for YAP, TAZ, phospho-Rb, GAPDH and ACTIN
(A). Phospho-Rb levels were quantiﬁed by densitometry (B; n = 3). siRNA-transfected
cellswere labelledwith BrdUbetween 24 and 36 h post transfection (C; n=3). * indicates
p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
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function of YAP and TAZ as co-factors for TEAD-family transcription
factors, reduction in nuclear YAP and TAZ resulted in reduced TEAD-
dependent reporter gene activity. We did not observe any effects of
cAMP on total YAP levels, despite previous work implicating YAP phos-
phorylation on serine-397 (annotated as S-381 by Zhao [40]) in priming
YAP degradation. Furthermore, we went on to demonstrate that cAMP
induced growth-arrest is associated with repression of a set of YAP/
TAZ-dependent proliferation genes (i.e. CCN1, CTGF, c-MYC and TGFB2)
in VSMC. Expression of these genes is repressed either by YAP/TAZ si-
lencing or cAMP elevation. Moreover, constitutively-active YAP or TAZ
phospho-mutants reversed, to varying degrees, the inhibitory effects
of forskolin, conﬁrming a functional role of YAP/TAZ in mediating the
effects of cAMP on these genes. Importantly, expression of all of these
genes have been associated with vascular remodelling in vivo and
functionally linked to increased VSMC proliferation [35,46,47]. Our
new data suggests that expression of these genes in VSMC is depen-
dent on YAP and TAZ and subject to repression by elevated cAMP.
The implication is that inhibition of these genes contributes towards
the anti-mitogenic effects of cAMP in VSMC. Our data showing
increased phosphorylation of YAP and TAZ by the prostacyclin
analogue also suggests that endothelial derived prostacyclin may
play a role in maintaining VSMC quiescence in healthy vessels via
this mechanism. Taken together, these observations indicate that
cAMP-mediated inhibition of YAP and TAZ and the subsequent
inhibition of TEAD-dependent transcription is an important early
mechanism underlying cAMP anti-mitogenesis in VSMC.
YAP and TAZ have been previously implicated in the regulation of
cell proliferation in several nonvascular cell types. For example, over
expression of Yorkie, the Drosophila homolog of YAP results in robust
tissue over growth phenotype. In mammals, forced expression of active
mutants of YAP or TAZ stimulate ﬁbroblast, epithelial and mammary
Fig. 7. The YAP–TEAD inhibitor Veteporﬁn inhibits VSMC proliferation. VSMC were
transfected with TEAD-luciferase reporter plasmid (8xTEAD) or a TnT-minimal promot-
er-luciferase plasmid (TnT-minP) and treated with the indicated concentrations of
Verteporﬁn for 8 h (A; n = 3). VSMCs were treated with the indicated concentrations of
Verteporﬁn for 18 h and total cell lysates analysed for phospho-Rb, GAPDH and ACTIN
levels byWestern blotting (B). Phospho-RbWestern blots were quantiﬁed by densitome-
try (C; n = 3). VSMCs were treated with Verteporﬁn for 18 h followed by BrdU labelling
for 6 h (D; n = 3). * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
Fig. 8. Constitutively active YAP and TAZ reverse the anti-mitogenic effect of forskolin in
VSMC. VSMCs were infected with 3 × 107 pfu/ml of control adenovirus or adenovirus
expressing constitutively active YAPS127A or TAZ4SA. Cells were stimulated with 25 μM
forskolin for 18 h (A and B). Total cell lysates were analysed for phospho-Rb levels by
Western blotting and densitometry (A; n = 3). Cells were labelled with BrDU for 6 h
immediately after forskolin stimulations (B; n = 3). * indicates p b 0.05, ** indicates
p b 0.01, *** indicates p b 0.001.
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carcinoma cell proliferation and migration, whereas expression of
dominant-negative mutants or siRNA silencing inhibits it [48–51], con-
sistent with our ﬁndings. Complementing its role in adult VSMC, YAP
also inﬂuences cardiovascular development and homeostasis. Loss of
YAP in the murine cardiovascular system results in perinatal lethality,
while YAP conditional knockout mice exhibit impaired embryonic
VSMC proliferation leading to severe vascular abnormalities including
thinning vascular walls and short/absent brachiocephalic arteries [52].
Thismay reﬂect the known role of YAP in VSMCphenotypicmodulation
[53]. TEAD-dependent transcription has also been linked to regulation
of cell proliferation in several species and cell types. In Drosophila, the
TEAD-homolog, Scalloped has been shown to mediate the overgrowth
phenotype of the Yorkie. Furthermore, the mitogenic properties of
YAP are dependent on its ability to enhance TEAD transcriptional activ-
ity, since TEAD silencing blocks expression of themajority of YAP induc-
ible genes and largely attenuates YAP-induced overgrowth phenotype
[28]. Furthermore, the phenotype of the TEAD1/2-null mice resembles
the phenotype of YAP-null mice [29].
Elevated levels of cAMP arrest VSMC in G1 phase of the cell-cycle,
at least in part through inhibition of G1-regulatory proteins CYCLIN-
D1 and SKP2 [41,54]. However, these events occur relatively late in
G1-phase and these genes are unlikely to be direct targets of the
YAP/TAZ–TEAD pathway. Neither contain TEAD binding elements
in their proximal promoters and their repression by cAMP is delayed
(taking several hours) compared to the YAP/TAZ targets we describe
here. However, CYCLIN-D1 expression is enhanced in response to
CTGF and CCN1 stimulation [46,55], suggesting that CYCLIN-D1 re-
pressionmay occur, at least in part, due to the early and direct effects
on CCN1 and CTGF. Reduced CYCLIN-D1 expression will slow cell-
cycle progression by limiting cdk4 activity and preventing E2F
activation. E2F positively regulates SKP2 transcription as part of a
positive auto-induction loop the drives cells into S-phase. Taken to-
gether, this suggest that cAMP-mediated inhibition of YAP/TAZ tar-
get genes not only precedes but may also contribute towards the
later inhibition of CYCLIN-D1 and SKP2 and represent the earliest
mechanisms underlying cAMP anti-mitogenesis. Deﬁning these
early mechanisms could have an important impact on development
of new pharmacological approaches to combat cardiovascular
disease.
Given the importance of YAP/TAZ in the regulation of cell prolifera-
tion, recent attention has focussed on characterising the upstream sig-
nals that regulate YAP/TAZ activity. Notably, signals that modulate
actin-cytoskeleton organisation appear to be particularly important.
These includemechanical, cell–cell contact andmitogenic growth factor
signals. Our new data demonstrates that cAMP-mediated actin-
cytoskeleton remodelling is also an important mechanism that nega-
tively regulates YAP/TAZ activity in VSMC. Elevated cAMP inhibits the
activity of members of the Rho GTPases, including RhoA and Rac1
[19–21], rapidly inhibiting actin-polymerisation and inducing a ‘stellate’
morphology, characterised by a condensed cytoplasm and loss of actin
stress-ﬁbres. RhoGTPase activity promotes VSMC proliferation and sub-
sequent intima formation following balloon injury and forced expres-
sion of constitutively-active Rho GTPase mutants prevents cAMP-
induced actin-cytoskeleton remodelling and rescues VSMCproliferation
[19], demonstrating that inhibition of Rho GTPase-dependent actin-
cytoskeleton polymerisation plays a decisive role in cAMP anti-
mitogenesis in VSMC. Precisely how these cAMP induced actin changes
modulate VSMC behaviour has remained poorly understood. Our new
data suggests that cAMP counteracts the effects of diverse mitogenic
signals by inhibiting Rho GTPasemediated actin-cytoskeleton remodel-
ling. In turn, this inhibits the YAP/TAZ-TEAD-dependent expression of
proliferation genes. Given that many mitogenic signals act, at least in
part, via positive regulation of the RhoA-actin pathway, this implies
that regulation of YAP/TAZ is an important central node formultiplemi-
togenic and anti-mitogenic signalling pathways and as suchmay repre-
sent a valuable target for future anti-proliferative therapies.
Proliferation of VSMC is a major factor that contributes towards
pathological intimal thickening underlying numerous vascular patholo-
gies, including late vein graft failure, in-stent restenosis, pulmonary ar-
tery hypertension and atherosclerosis. Intracellular cAMP is a major
second messenger involved in the regulation of VSMC proliferation.
The ability of vascular cells to synthesise cAMP is high in healthy vessels
where it contributes towards the maintenance of VSMC quiescence.
Reduced synthesis of cAMP after vessel injury or during disease is likely
to be an importantmechanism in removing the “brake” on proliferation.
A large body of evidence documents the anti-mitogenic properties of
cAMP in VSMC and ultimately its ability to repress intima formation
in vivo [41]. However, translating knowledge of cAMP signalling into
clinically useful therapy has also been challenging mainly owing to the
multiple cell-type speciﬁc effects of the cAMP system. Direct targeting
of speciﬁc cAMP-sensitive pathways may therefore be a valuable strat-
egy to harness the beneﬁcial effects of cAMP whilst avoiding unwanted
side effects. Interestingly, the ability of the benzoporphyrin derivative,
Verteporﬁn to block the interaction between YAP and TEAD demon-
strates that this protein:protein interaction is amenable to small-
molecule antagonism, raising the hope for future YAP/TAZ based
therapies.
Glossary
BrdU 5-Bromo-2-deoxyuridine
cAMP 3′-5′-cyclic adenosine monophosphate
CREB cAMP Response Element Binding Protein
SRF Serum Response Factor
VSMC Vascular Smooth Muscle Cell
RhoA Ras Homolog Family Member A
Rac Ras-related C3 botulinum toxin substrate 1
VSMC Vascular Smooth Muscle Cell
YAP Yes-Associated Protein-1
TAZ Transcriptional Co-Activator with PDZ-Binding Motif
TEAD TEA Domain Family Member
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